Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12284558 | 1.00 | ANPEP (0.50) | ANPEPMMP2KDM4ENPC1CYP3A4 | |
| SCHEMBL2148264 | 0.93 | MMP2 (0.45) | ANPEPMMP2KDM4ENPC1CYP3A4 | |
| SCHEMBL18657109 | 0.93 | MMP2 (0.45) | ANPEPMMP2KDM4ENPC1CYP3A4 | |
| SCHEMBL3345460 | 0.93 | MMP2 (0.45) | ANPEPMMP2KDM4ENPC1CYP3A4 | |
| SCHEMBL14685401 | 0.92 | MMP2 (0.44) | ANPEPMMP2KDM4ENPC1CYP3A4 | |
| SCHEMBL2297429 | 0.92 | MMP2 (0.44) | ANPEPMMP2KDM4ENPC1CYP3A4 | |
| SCHEMBL21000141 | 0.91 | ANPEP (0.43) | ANPEPMMP2KDM4ENPC1CYP3A4 | |
| SCHEMBL14439895 | 0.91 | MMP2 (0.43) | ANPEPMMP2KDM4ENPC1CYP3A4 | |
| SCHEMBL30706553 | 0.91 | MMP2 (0.43) | ANPEPMMP2KDM4ENPC1CYP3A4 | |
| SCHEMBL18313951 | 0.89 | KDM4E (0.47) | ANPEPMMP2KDM4ENPC1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575955-B1 | PYRROLOBENZODIAZEPINES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN LTD (GB) | 2011-02-09 | — | — | EP | disclosed |
| EP-1575955-B1 | PYRROLOBENZODIAZEPINES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN LTD (GB) | 2011-02-09 | — | — | EP | disclosed |
| US-7407951-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| US-7407951-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| US-7407951-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| US-7067511-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-20060128693-A1 | Pyrrolobenzodiazepines | MEDIMMUNE LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
| US-7049311-B1 | Pyrrolbenzodiazepines | SPIROGEN LIMITED (GB) | 2006-05-23 | — | — | US | disclosed |
| EP-1109812-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2005-05-04 | — | — | EP | disclosed |
| EP-1413582-A1 | Dimeric pyrrolobenzodiazepines | Spirogen Limited (GB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030120069-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-06-26 | — | — | US | disclosed |
| EP-1193270-A2 | Pyrrolobenzodiazepines | Spirogen Limited (GB) | 2002-04-03 | — | — | EP | disclosed |
| EP-1109812-A2 | PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012508-A2 | PYRROLBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120069-A1 | Pyrrolobenzodiazepines | CNR1, CBX2, CNR2 | ANPEP 3439/4885MMP2 4590/4885KDM4E 2997/4885 |
| US-20060128693-A1 | Pyrrolobenzodiazepines | CYP2C19, CYP3A7, CYP2E1 | ANPEP 2003/4885MMP2 3002/4885KDM4E 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.